Table 2.
Annual Pharmacological costs and costs of the health states, transient events, mortality and adverse events (€/2023)
| Parameter | Mean cost (SEa) | Distribution | Reference |
|---|---|---|---|
| Pharmacological treatment (€, annual) | |||
| Dapagliflozin | 355.71 | - | [40, 41] |
| SoCb | 418.66 | - | [7, 40, 41] |
| Health states (€, annual) | |||
| KCCQ-TSS Q1 | 1,519.25 (303.85) | Gamma | [42, 43] |
| KCCQ-TSS Q2 | 1,387.14 (277.43) | Gamma | [42, 43] |
| KCCQ-TSS Q3 | 1,255.03 (251.01) | Gamma | [42, 43] |
| KCCQ-TSS Q4 | 1,122.92 (224.58) | Gamma | [42, 43] |
| Transient event (€, event) | |||
| HHF | 4,057.97 (811.59) | Gamma | [44] |
| UHFV | 243.21 (48.64) | Gamma | [43] |
| Mortality (€, event) | |||
| CV death | 8,785.76 (1,757.15) | Gamma | [44] |
| AEs (€, event) | |||
| AKI | 4,968.48 (993.70) | Gamma | [44] |
| Amputation | 13,945.88 (2,789.18) | Gamma | [43] |
| Fracture | 7,541.16 (1,508.23) | Gamma | [43] |
| UTI | 59.54 (11.91) | Gamma | [43] |
| Volume depletion | 59.54 (11.91) | Gamma | [43] |
aA 20% SE was assumed for all parameters
bThe weighted SoC cost assumes that 41.9% of the patients with LVEF > 40% and 58.1% with LVEF ≤ 40% [7]
Abbreviations: AE Adverse event, AKI Acute kidney injury, CV Cardiovascular, HHF Hospitalization for heart failure, KCCQ Kansas City Cardiomyopathy Questionnaire, LVEF Left ventricular ejection fraction, SE standard error, SoC Standard of care, TSS Total symptom score, UHFV Urgent heart failure visit, UTI Urinary tract infection